Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Actinium Pharmaceuticals develops targeted radiotherapies using alpha-emitting isotopes to treat advanced cancers, including myeloid malignancies, solid tumors, and conditioning for cell and gene therapies. Its clinical-stage pipeline features Actimab-A for AML and MDS, Iomab-ACT for conditioning prior to cellular therapies, and ATNM-400 for prostate cancer. The company integrates radioisotope production, drug manufacturing, and clinical development, leveraging proprietary Ac-225 technology and a broad patent portfolio.
This description was generated via AI from an annual report. Updated about 1 year ago.